In an expansion cohort of a phase I CHRYSALIS study, the RP2CD (recommended phase 2 combination dose) of amivantamab antibody combined with 3rd generation EGFR TKI lazertinib to exam patients in osimertinib resistant(n=45) or treatment-naïve(n=20) EGFR-positive (exon 19 deletions and L858R) NSCLCs. In osimertinib resistant group, the objective response rate(ORR) was 36% with one patient complete response, response was seen irrespective of first or second lines used osimertinib.
